Clinical Management Updates for Novel Corona Virus (COVID-19)
DOI:
https://doi.org/10.37285/ijpsn.2021.14.3.1Abstract
The SARS-CoV-2 virus was first detected in Wuhan, China in December 2019 and was known to produce acute severe respiratory illness in humans which rapidly spread almost throughout the world within a few months. This human coronavirus has seven strains and they commonly produce illness in the nervous system, respiratory system and hepato- intestinal systems. This present review is an attempt to illustrate recent reports pertaining to the management of SARS-CoV-2. Further, it also highlights the diagnosis and clinical management of COVID-19. Various search engines like Scopus, Pubmed and WHO databases were accessed and literature on current advances about COVID-19 including structural features, replication, possible pathogenic, symptoms, diagnosis, prognosis, methods of prevention and possible therapeutic agents used for treatment of patients was reviewed. Current studies indicate that COVID-19 is very infectious with droplet transmission potential. The key modalities to prevent the infection is by keeping social distancing, respiratory/hand hygiene, detection of infection and subsequent quarantine of the infected persons. Presently, either no vaccine for prevention or specific treatments available, however, COVID-19 patients may be managed by using some repositioned drugs and symptomatic treatment.
Downloads
Metrics
Keywords:
COVID-19, Symptoms, Diagnosis, Prevention, Cure, Clinical management
Downloads
Published
How to Cite
Issue
Section
References
bovine coronavirus spike protein and identification of the internal proteolytic cleavage site. Virology.176: 296-301.
Al Sulayyim HJ, Khorshid SM and Al Moummar SH (2020). Demographic, clinical and outcomes of confirmed cases of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in Najran, Kingdom of Saudi Arabia (KSA); A retrospective record-based study. J Infect Public Health S1876-0341(20); 30444-5.
Al-Bari MAA (2017). Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect 5(1): e00293.
Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF and Neher RA (2020) 2019 novel coronavirus (2019-nCoV): Estimating the case fatality rate - A word of caution. Swiss. Med Wkly 150: w20203.
Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H and Jiao JA (2018). Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis 18(4): 410-418.
Beniac DR andonov A and Grudeski E (2006). Architecture of the SARS coronavirus prefusion spike. Nat Struct Mol Biol 13: 751-752.
Bos EC, Luytjes W and van der Meulen HV (1996). The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus. Virology 218: 52-60.
Bosch BJ, van der Zee R and de Haan CA (2003). The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 77: 8801-811.
Chan JF, Yuan S, Kok KH, To KK, Chu H and Yang J (2020). A familial cluster of pneumonia associated with the 2019 novel corona virus indicating person-to-person transmission: a study of a family cluster. Lancet 30154-9.
Chang CK, Hou MH, Chang CF, Hsiao CD and Huang TH (2014). The SARS coronavirus nucleocapsid protein forms and functions. Antiviral Research. 103: 39-50.
Chang CK, Sue SC and Yu TH (2006). Modular organization of SARS corona virus nucleocapsid protein. J Biomed Sci 13: 59-72.
Cheng PK, Wong DA and Tong LK (2004). Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet 363:1699-170.
Chibo D and Birch C (2006). Analysis of human coronavirus 229E spike and nucleoprotein genes demonstrates genetic drift between chronologically distinct strains. J Gen Virol 87: 1203-1208.
Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH and Chan KS (2004). Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59(3): 252-6.
Collins AR, Knobler RL and Powell H (1982), Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell–cell fusion. Virology 119: 358-371.
De Backer D and Dorman T (2017). Surviving Sepsis Guidelines: a continuous move toward better care of patients with sepsis”. JAMA 317(8):807-808.
De Diego ML, Alvarez E and Almazan F (2007). A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J Virol 81: 1701-713.
Delmas B and Laude H (1990). Assembly of coronavirus spike protein into trimers and its role in epitope expression. J Virol 64: 5367-375.
Drosten C, Gunther S, Preiser W, Van der Werf S and Brodt (2003). Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 15; 348(20): 1967-76.
Eckerle, Lu, Sperry, Choi and Denison (2007). High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. J Virol 81:12135-12144.
Elfiky AA (2020). Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 248:117477-6.
Emery SL, Erdman DD and Bowen MD (2004). Real-time reverse transcription- polymerase chain reaction assay for SARS- associated coronavirus. Emerg Infect Dis 10: 311-316.
Falsey AR, McCann RM, Hall WJ, et al (1997). The “common cold” in frail older persons: impact of rhinovirus and coronavirus in a senior daycarecenter. J Am Geriatr Soc45:706-711.
Falsey AR, Walsh EE and Hayden FG (2002). Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J Infect Dis 185:1338-1341.
Fehr AR and Perlman S (2015). Corona viruses: an overview of their replication and pathogenesis. Methods Mol Biol 1282:1-23.
Fehr AR, Perlman S, Maier HJ, Bickerton E and Britton P (2015). An Overview of Their Replication and Pathogenesis; Section 2 Genomic Organization". Methods in Molecular Biology. Springer 1282: 1-23.
Ferrey AJ, Choi G, Hanna RM, Chang Y, Tantisattamo E and Ivaturi K (2020). A Case of Novel Coronavirus Disease 19 in a Chronic Haemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease. Am J Nehru 28: 1-6.
Frank Esper, Carla Weibel, David Ferguson, Marie L. Landry, Jeffrey and Kahn S (2006). Coronavirus HKU1 Infection in the United States. Emerging Infectious Diseases 12(5): 775-779.
Gaunt ER, Hardie A and Claas EC (2010). Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63 and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol 48: 2940-2947.
Godet M, LHaridon R and Vautherot JF (1992). TGEV corona virus ORF4 encodes a membrane protein that is incorporated into virions. Virology 188: 666-675
Goldsmith CS, Tatti KM, Ksiazek TG, Rollin PE, Comer JA and Lee WW (2004). Ultrastructural characterization of SARS coronavirus". Emerging Infectious Diseases 10(2): 320-326.
Graham RL, Donaldson EF and Baric RS (2013). A decade after SARS: Strategies for controlling emerging coronaviruses. Nat Rev Microbiol.11: 836-482.
Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW and Li PH (2003) Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302: 276-278.
Guangyu Z and Qi Z (2020). Perspectives on therapeutic neutralizing antibodies against the novel Coronavirus SARS-CoV-2. Int J Biol Sci.16(10):1718-1723.
Guo J, Xie H, Liang M and Wu H (2020), COVID-19 a novel coronavirus and a novel challenge for oral healthcare. Clin Oral Investig 10: 1007/s00784.
Hamre D and ProcknowJJ (1966). A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med 121:190-193.
Hamzah ZF, EmmaD, ShazaadA, NicholasM, MalcolmG and Andrew Turner J (2020). Middle East respiratory syndrome coronavirus (MERS-CoV)- Surveillance and testing in North England from 2012 to 2019. International Journal of Infectious Diseases 93: 237-244.
Hurst KR, Koetzner CA and Masters PS (2009). Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein. J. Virol 83: 7221-7234.
Ip VHY, Sondekoppam RV, Ozelsel TJP and Tsui BCH (2020). Coronavirus disease 2019 (COVID-19) pandemic: International variation of personal protective equipment (PPE) and infection prevention and control (IPC) guidelines. AnesthAnalg 10 (1213): 1-6
James H McMahon AndrewUdy and Anton YP (2020). Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med 10; 383:10.1056.
Jan H, Faisal S, Khan A, Khan S, Usman H, Liaqat R and Shah SA (2020). COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries (Craiova) 26; 8(2): e108.
Kahn JS and McIntosh K (2005). History and recent advances in coronavirus discovery. Pediatr Infect Dis J 24 (11Suppl): S223-7.
Kubo H, Yamada YK and Taguchi F (1994). Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein. J Virol 68: 5403-410.
Lai MM and Cavanagh D (2019). The molecular biology of coronaviruses. Advances in Virus Research 48: 1-100.
Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, Wong SS, Leung SY, Chan KH and Yuen KY (2005). Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proceedings of the National Academy of Sciences of the United States of America 102(39):14040-14045.
LeeN, Allen Chan KC, Hui DS, Ng EK, Wu A and Chiu RW (2004). Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 31(4): 304-9.
Li F, Li W, Farzan M and Harrison SC (2005). Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309 (5742): 1864-1868.
Li W, Moore MJ and Vasilieva N (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426: 450-454.
Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H and Zhang J (2005). Bats are natural reservoirs of SARS-like coronaviruses. Science 310(5748): 676-679.
Liu C, Zhou Q, Li Y, Linda V. Garner L V and Watkins SP (2020). Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases”. ACS Cent. Sci 6(3): 315-331.
LuytjesW, Sturman LS and Bredenbeek PJ (1987). Primary structure of the glycoprotein E2 of coronavirus MHV-A59 and identification of the trypsin cleavage site. Virology 161: 479-487.
McIntosh K, Becker WB and Chanock RM (1967). Growth in suckling-mouse brain of “IBV-like” viruses from patients with upper respiratory tract disease. Proc Natl Acad Sci U S A58: 2268-273.
McIntosh K, Ellis EF, Hoffman LS, Lybass TG, Eller JJ and Fulginiti VA (1973). Association of viral and bacterial respiratory infection with exacerbations of wheezing in young asthmatic children. Chest 63(suppl): 43S.
Meo S.A., Klonoff D.C. and Akram J (2020). Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur Rev Med Pharmacol Sci 24 (8): 4539-4547.
Molenkamp R and Span WJ (1997). Identification of a specific interaction between the coronavirus mouse hepatitis virus A59 nucleocapsid protein and packaging signal. Virology 239: 78-86.
Neuman BW, Adair BD, Yoshioka C, Quispe JD, Orca G and Kuhn P (2006). Supramolecular architecture of severe acute respiratory syndrome corona virus revealed by electron cryomicroscopy. Journal of Virology 80 (16): 7918-7928.
Neuman BW, Kiss G, Kunding AH, Bhella D, Baksh MF and Connelly S (2011). A structural analysis of M protein in coronavirus assembly and morphology. Journal of Structural Biology 174(1): 11-22.
Nieto-Torres JL, Dediego ML and Verdia- Baguena C (2014). Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoSPathog 10(5): e1004077.
QunLi, Xuhua Guan and Peng Wu (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med 382(13): 1199-1207.
Romette JL (2018). The European Virus Archive goes global: A growing resource for research. Antiviral Res 158:127-134.
Rota P, Oberste S and Monroe S (2003). Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome Science 300(5624): 1394-9.
Sahar AR and Burtram CF (2010). Understanding Human Coronavirus HCoV-NL63. Open Virol J 4: 76-84.
Schoeman D and Fielding BC (2019). Coronavirus envelope protein: current knowledge. Virol J 16(69): 1-22
Sethna PB, Hofmann MA and Brian DA (1991). Minus-strand copies of replicating coronavirus mRNAs contain antileaders. J Virol 65: 320-325.
Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB and Denison MR (2016). Homology-Based Identification of a Mutation in the Coronavirus RNA-Dependent RNA polymerase that Confers Resistance to Multiple Mutagens. Journal of Virology 90(16): 7415-7428.
Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J and Brown AJ (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir and interferon beta against MERS-CoV. Nat Commun 11(222):13940-6.
Shio-Shin Jean and Ping-Ing Lee PH (2020). Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect 53(3):436-443.
Simmons G, Zmora P, Gierer S, Heurich A and Pohlmann S (2013). Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral Research 100 (3): 605-614.
Siu YL, Teoh KT and Lo J (2008). The M, E and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking and release of virus-like particles. J Virol 82:11318-11330.
Smith, Case, Blanc, Isakov, Shomron, Vignuzzi and Denison N (2015). Mutations in coronavirus nonstructural protein 10 decrease virus replication fidelity. J Virol 89: 6418-6426.
Stohlman SA, Baric RS and Nelson GN (1988). Specific interaction between coronavirus leader RNA and nucleocapsid protein. J Virol 62: 4288-4295.
Van der Hoek L, Pyrc K and Jebbink MF (2004). Identification of a new human coronavirus. Nat Med 1004: 10: 368-373.
Van der Hoek L, Sure K and Ihorst G (2005). Croup is associated with the novel coronavirus NL63. PLoS Med. 2: e240.
Vijgen L, Keyaerts E and Lemey P (2005). Circulation of genetically distinct contemporary human coronavirus OC43 strains. Virology 337: 85-92.
Wang M (2020). Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan. medRxiv preprint: 1: 1-18.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W and Xiao G (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3): 269-271.
WHO Coronavirus Disease 2019 (COVID-19). WHO; 2020. Health topic/Coronavirus.
Woo PC, Lau SK and Chu CM (2005). Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 79: 884-889.
Yang R and Yu H (2004). The Spike Protein of Severe Acute Respiratory Syndrome (SARS) Is Cleaved in Vírus Infected Vero-E6 cells, China. Cell Research. 14(5): 400-406.
Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, Sun J and Chang C (2020). The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 109:102434.
Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY and Loh J (2020). Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA 3: 10. 1001.
Yount, Denison, Weiss and Baric (2002). Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol 76:11065-11078.
Zheng BJ and He YQ (2003). Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302: 276-278.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J and Wang Y (2020). Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054-1062.
